Summary of Key Points Core Viewpoint - On July 11, 13 stocks from the Sci-Tech Innovation Board experienced block trading, with a total transaction amount of 256 million yuan, indicating active trading in this sector [1]. Group 1: Trading Activity - A total of 13 Sci-Tech Innovation Board stocks had block trades, with 26 transactions and a cumulative trading volume of 13.93 million shares [1]. - The stock with the highest transaction amount was Weiteng Electric, with a trading volume of 2.34 million shares and a transaction amount of 63.52 million yuan [1]. - Other notable stocks in terms of transaction amounts included Huicheng Co. and Yunzhu Technology, with transaction amounts of 57.27 million yuan and 23.83 million yuan, respectively [1]. Group 2: Price Performance - The average price of the stocks involved in block trading showed a discount compared to the closing price, with the highest discount rates for Weimais, Dameng Data, and Fuje Environmental Protection at 25.02%, 21.16%, and 19.12% respectively [1]. - In contrast, Huicheng Co. had a premium rate of 0.93% [1]. - The Sci-Tech 50 Index rose by 1.48%, with 402 stocks (68.25%) increasing in value, while the average increase for stocks involved in block trading was 3.58% [1]. Group 3: Institutional Participation - Among the block trades, 12 transactions involved institutional buyers or sellers, focusing on four stocks, with the highest buying amounts in Fuje Environmental Protection, Aopumai, and Yifang Bio at 14.08 million yuan, 10.49 million yuan, and 10.01 million yuan, respectively [2]. - Net inflows of funds were observed in six stocks, with Yifang Bio, Huazhu High-Tech, and Kaiweite leading in net inflow amounts of 16.69 million yuan, 5.53 million yuan, and 5.47 million yuan, respectively [2]. - Conversely, Yunzhu Technology, Haimeixing, and Fuchuang Precision experienced the highest net outflows of 8.99 million yuan, 7.35 million yuan, and 3.13 million yuan, respectively [2].

Core Viewpoint - The article highlights a significant surge in merger and acquisition (M&A) activities in the A-share market, driven by policy optimizations and an increase in the number of major asset restructurings, with a notable year-on-year growth in transaction volume and frequency [1][5]. Group 1: M&A Activity and Statistics - Since September 2024, there have been nearly 200 major asset restructurings in the A-share market, marking a substantial increase compared to previous periods [1]. - In 2024, 44 brokerage firms acted as independent financial advisors for M&A projects, with the top three firms—CICC, CITIC Securities, and Huatai Securities—leading in transaction numbers [2][3]. - The top three brokerages completed 32, 30, and 23 transactions respectively, while six other firms completed more than five transactions each [3]. - The total transaction value for the top three brokerages exceeded 1 trillion yuan, with CITIC Securities leading at 202.46 billion yuan, followed by CICC at 145.736 billion yuan, and China Post Securities at 116.367 billion yuan [3]. Group 2: Policy Support and Regulatory Changes - Recent policy changes have aimed to enhance the M&A environment, including a meeting held by the CSRC in February 2024 to discuss optimizing M&A regulations and supporting listed companies [6]. - The "Eight Measures" released in June 2024 by the CSRC emphasized stronger support for M&A activities, establishing a "green channel" for M&A processes [7]. - In September 2024, the CSRC issued the "Six Opinions" to further reform the M&A market, promoting cross-industry mergers based on transformation and upgrading [8]. Group 3: Industry Trends and Implications - The article notes that M&A activities are crucial for economic transformation and enhancing market vitality, particularly for emerging industries facing funding challenges [9]. - The integration of technology assets through M&A has been facilitated by recent policy changes, allowing companies to overcome previous barriers [10]. - The number of M&A cases in the electronics and computer sectors has significantly increased, with the proportion of M&A events in the Sci-Tech Innovation Board rising from 4% in 2023 to 18% in the first half of 2025 [10]. Group 4: Securities Industry M&A Highlights - The securities industry has seen notable M&A activities, including the merger of Guotai Junan and Haitong Securities, creating the largest A+H dual market merger case [11]. - Other significant transactions include the merger of Xiangcai Co. with Dazhihui and the acquisition of Wanhua Securities by Guoxin Securities [11]. - M&A in the securities sector is viewed as an effective means for firms to achieve external growth and enhance overall industry competitiveness [12].

Group 1 - The A-share professional service sector experienced a short-term rise, with Guangdian Measurement increasing by over 5% after a rebound, and stocks such as Keri International, Aopu Mai, and Zhongjin Radiation also following suit [1] - The Ministry of Industry and Information Technology issued the "Measurement Support for New Quality Productivity Development Action Plan (2025-2030)", which emphasizes key technological breakthroughs in measurement for new-generation display, communication, and chip information fields [1]

Core Viewpoint - The company reported a revenue of 297 million yuan for 2024, representing a year-on-year growth of 22.26%, with significant variations across different product lines and services [3][4][6]. Revenue and Gross Margin Analysis - The revenue breakdown shows that CHO culture media revenue increased by 62.83%, while CDMO service revenue declined by 25.66% [3][16]. - The gross margin for domestic CDMO services dropped significantly, while the gross margin for culture media remained relatively stable [24][25]. Product Sales Performance - CHO culture media sales in the domestic market reached 126.05 million yuan, a 33.01% increase, driven by ongoing customer projects [11][12]. - The sales volume of 293 culture media decreased by 16.28% in the domestic market due to lower demand in related application fields [12][13]. - Other products, including contract manufacturing and vaccine culture media, saw a notable increase in revenue due to stable orders from overseas clients [13][15]. CDMO Business Challenges - The CDMO business faced a significant decline in revenue, attributed to a tightening financing environment in the biopharmaceutical industry, leading to reduced project initiation and progression [35]. - The number of high-value orders (over 5 million yuan) significantly decreased, impacting overall revenue [17][35]. - The company reported a negative gross margin for CDMO services in 2024, primarily due to increased material costs and operational expenses from the new commercial production platform [35][36]. Customer and Market Dynamics - The company’s top five overseas clients contributed significantly to revenue growth, with notable increases in sales to key customers [20][22]. - The overall customer base remained stable, but the number of high-value clients decreased, reflecting a challenging market environment [7][35]. - The company continues to focus on providing high-quality CDMO services despite facing increased competition and cost pressures [35].

立信会计师事务所（特殊普通合伙） 关于上海奥浦迈生物科技股份有限公司 2024 年年度报告的信息披露监管问询函的回复 信会师函字[2025]第 ZA262 号 上海证券交易所： 贵所于2025年6月6日出具的《关于上海奥浦迈生物科技股份有限公司2024年年 度报告的信息披露监管问询函》（上证科创公函【2025】0240号）（以下简称"问 询函"）已收悉。立信会计师事务所（特殊普通合伙（）以下简称"我们"、"会 计师"或"年审会计师"）作为上海奥浦迈生物科技股份有限公司（以下简称"公 司"或"奥浦迈"）2024年度年审会计师，对问询函中需要会计师说明的问题 进行了认真核查，现回复如下： （注：如无特别说明，本回复所使用的名词释义与奥浦迈2024年年报一致；回 复数值若出现总数与各分项数值之和尾数不符的情况，均为四舍五入原因造成。 鉴于部分信息涉及公司商业敏感信息，因此针对该部分内容进行豁免披露。） 问询函回复 第1页 问题一、关于营业收入和毛利率。公司 2024 年实现营业收入 2.97 亿元，同 比增长 22.26%。分业务看，CHO 培养基、293 培养基、其他产品营业收入同比 变化幅度分别为 49.02% ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-057 上海奥浦迈生物科技股份有限公司 关于 2024 年年度报告的信息披露监管问询函的回复 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）于2025 年6月6日收到上海证券交易所科创板公司管理部下发的《关于上海奥浦迈生物科 技股份有限公司2024年年度报告的信息披露监管问询函》（上证科创公函【2025】 0240号）（以下简称"《问询函》"或"《2024年年报问询函》"）。根据《问 询函》的要求，公司与2024年度财务报告审计机构立信会计师事务所（特殊普通 合伙）（以下简称"年审会计师"）对《问询函》提及的相关事项进行了认真核 查。 现就相关问题回复如下： （说明：如无特别说明，本回复公告中使用的名词释义与公司《2024年年度 报告》保持一致，本回复公告中若出现合计数与各分项数值相加之和在尾数上存 在差异的情况，均为四舍五入所致。鉴于部分信息涉及商业敏感信息，根据相关 法律法规、规范性文件的 ...

证券代码：688293 证券简称：奥浦迈 上市地点：上海证券交易所 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套 资金报告书（草案）（申报稿） | 项目 | 交易对方 | | --- | --- | | | PharmaLegacy Hong Kong Limited、嘉兴汇拓企业管理合伙企业 | | | （有限合伙）、红杉恒辰（厦门）股权投资合伙企业（有限合 | | | 伙）、宁波梅山保税港区谷笙澎立投资合伙企业（有限合伙）、 | | | TF PL LTD.、上海高瓴辰钧股权投资合伙企业（有限合伙）、杭 | | | 州泰格股权投资合伙企业（有限合伙）、南通东证富象股权投资 | | | 中心（有限合伙）、江西济麟鑫盛企业管理有限公司、中金启辰 | | | 贰期（苏州）新兴产业股权投资基金合伙企业（有限合伙）、嘉 | | | 兴合拓企业管理合伙企业（有限合伙）、苏州晨岭投资合伙企业 | | | （有限合伙）、德州两仪幂方康健创业投资合伙企业（有限合 | | | 伙）、平阳国凯股权投资合伙企业（有限合伙）、苏州一元幂方 | | 发行股份及支付现金购买资产 | 医药创业投资合伙企业（有限合 ...

国泰海通证券股份有限公司 关于 上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套 资金 之 独立财务顾问报告 本独立财务顾问报告是依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管 理办法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市公司 重大资产重组》《上海证券交易所上市公司自律监管指引第 6 号—重大资产重组》 等法律、法规的有关规定，按照证券行业公认的业务标准、道德规范和诚实信用、 勤勉尽责精神，遵循客观、公正的原则，在认真审阅相关资料和充分了解本次交 易行为的基础上，发表独立财务顾问意见，旨在就本次交易做出独立、客观和公 正的评价，以供上海奥浦迈生物科技股份有限公司全体股东及有关方面参考。 一、独立财务顾问声明 （一）本独立财务顾问与本次交易所有当事方无任何利益关系，就本次交易 所发表的有关意见是完全独立的。 （二）本报告所依据的文件、材料由相关各方向本独立财务顾问提供。相关 各方对所提供的资料的真实性、准确性、完整性负责，相关各方保证不存在任何 虚假记载、误导性陈述或重大遗漏，并对所提供资料的合 ...

2-2 法律意见书 | 序号 | | 文件名 | 页码 | | --- | --- | --- | --- | | 1 | 法律意见书 | | 1 | | 2 | 补充法律意见书（一） | | 145 | 上海市方达律师事务所 关于上海奥浦迈生物科技股份有限公司 发行股份及支付现金购买资产并募集配套资金的 法律意见书 2025 年 6 月 FANGDA PARTNERS http://www.fangdalaw.com 2-2-1 | | | 释 义…………………………………………………………………………………………………….6 | | --- | --- | --- | | | | 正 文……………………………………………………………………………………………………13 | | 一、 | 本次交易方案 | 13 | | 二、 | 本次交易涉及的各方主体资格 | 29 | | 三、 | 本次交易的批准和授权 | 73 | | 四、 | 本次交易的相关协议 | 74 | | 五、 | 本次交易的标的资产 | 75 | | 六、 | 与本次交易有关的债权债务安排 | 110 | | 七、 | 与本次交易有关的职工安 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-056 上海奥浦迈生物科技股份有限公司 关于发行股份及支付现金购买资产并募集配套资金 报告书（草案）（申报稿） 修订说明的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海奥浦迈生物科技股份有限公司（以下简称"公司"或"上市公司"）拟 通过发行股份及支付现金方式购买澎立生物医药技术（上海）股份有限公司（以 下简称"澎立生物"或"标的公司"）100.00%股权（以下简称"本次发行股份及 支付现金购买资产"），并向不超过 35 名特定投资者发行股票募集配套资金（以 下简称"本次募集配套资金"，与本次发行股份及支付现金购买资产合称"本次 交易"）。 上海奥浦迈生物科技股份有限公司董事会 公司于 2025 年 6 月 27 日收到上海证券交易所出具的《关于受理上海奥浦迈 生物科技股份有限公司发行股份购买资产并募集配套资金申请的通知》（上证科 审（并购重组）〔2025〕20 号），详见与本公告同日披露的《关于发行股份及支 付现金购买资产并募集配套资金申请材料获得上 ...